• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mereo Biopharma Group Plc ADR (NQ: MREO )

    3.890 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 3.890
    Bid (Size) 3.740 (10)
    Ask (Size) 4.160 (9)
    Prev. Close 3.890
    Today's Range 3.890 - 3.890
    52wk Range 1.070 - 4.500
    Shares Outstanding 584,908,239
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga

    Performance

    YTD
    +69.13%
    +69.13%
    1 Month
    +27.96%
    +27.96%
    3 Month
    +31.42%
    +31.42%
    6 Month
    +89.76%
    +89.76%
    1 Year
    +190.30%
    +190.30%

    More News

    Read More
    MicroMarvel: Mereo BioPharma - Analysts Favorite
    Via Talk Markets
    Uber To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Why Oracle Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Why Is Mereo BioPharma Stock Trading Higher Today?
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
    From Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
    Via GlobeNewswire
    Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.